Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 13, 2019
Daily News
November 13, 2019
- Half of R&D Money Going towards Cancer Meds, Exec Says Oncology Will Be GSK’s “Next Respiratory”
November 13, 2019
- Astellas’ HIF-PH Inhibitor, Trintellix, Venclexta, and Many More OK’ed for Listing on Nov. 19
November 13, 2019
- Keytruda to Get 17.5% Price Cut in February
November 13, 2019
- JPWA Compares Traceability Regulations to Prevent Distribution of Counterfeit Drugs in Japan, US, EU
November 13, 2019
- AstraZeneca, Omron Healthcare Pair Up to Develop Disease Management Solutions
November 13, 2019
- Ono, BMS File Opdivo/Yervoy Combo for MSI-H Colorectal Cancer in Japan
November 13, 2019
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…